In this publication by T. Williams et al. explored the prognostic and predictive potential of CAV1/2 expression for early-stage HER2-negative breast cancer patients receiving neoadjuvant paclitaxel-based chemotherapy regimens.
Our findings indicate that high CAV1/2 expression is associated with worse Disease Free Survival (DFS) and Overall Survival (OS) in paclitaxel-treated patients. Conversely, in nab-paclitaxel-treated patients, high CAV1/2 expression is associated with increased pCR and no significant detriment to DFS or OS compared to low CAV1/2 expression.
Caveolin Gene Expression (CAV1/2) Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial. Clin Cancer Res (2023) 29 (17): 3384–3394.